A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnoza chłoniaka T-komórkowego (PTCL lub CTCL)
- •Wcześniejsze leczenie - przynajmniej jedna lub dwie poprzednie terapie (w zależności od typu chłoniaka)
- •Dostępne próbki tkanki guza do badania
- •Mierzalne zmiany nowotworu na badaniach
- •Dobry stan ogólny pacjenta
- •Prawidłowe wyniki badań krwi i funkcji nerek i wątroby
- •Waga od 40 do 200 kg
✗ Disqualifies
- •Przeszzczep szpiku w ostatnich 4 miesiącach
- •Ciąża, karmienie piersią lub planowanie ciąży
- •Aktywne zakażenie HIV, zapalenie wątroby B lub C
- •Aktywna lub nieleczona infekcja wymagająca leków przeciwzakaźnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (22)
City of Hope
Duarte, United States
University of California, Irvine Medical Center - Hematology/Oncology
Orange, United States
Stanford University School of Medicine
Stanford, United States
Moffit Cancer Center
Tampa, United States
Emory University Medical Center
Atlanta, United States
University of Iowa Health
Iowa City, United States
Beth Israel Deaconess Medical Center - Research
Boston, United States
Washington University School of Medicine - Oncology Hospital - Public
St Louis, United States
Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
Hackensack, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
Oregon Health & Science University
Portland, United States
University of Pennsylvania - Abramson Cancer Center
Philadelphia, United States
The University of Texas - MD Anderson Cancer Center
Houston, United States
Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
Candiolo, Italy
Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
Bergamo, Italy
Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
Bologna, Italy
AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
Torino, Italy
Hospital Clinic De Barcelona - Hematología
Badalona, Spain
Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
L'Hospitalet de Llobregat, Spain
Clinica Universidad de Navarra - Hematología
Pamplona, Spain
Clinica Universidad de Navarra - Hematología y Hemoterapia
Madrid, Spain
Trial contact
Kyowa Kirin, Inc.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.